This Review from Neurodegenerative Disease Management explores light therapy for Alzheimer’s disease and related dementias, and how to maximize treatment impact.
Browsing: Neurodegenerative Disease Management
Jutley et al. discuss established glaucoma treatments, review promising new neuroprotective agents, and explore potential future treatments targeting the neurodenegerative processes in glaucoma.
Amyloid positron emission tomography (aPET) measurement of Alzheimer’s disease (AD) pathology could improve the accurate diagnosis of cognitive disorders.
In this review, the authors discuss the history of DBS for Parkinson’s disease, as well as outcomes, recent advances, and where the field will go next.
In this review the authors explore an individualized approach to managing cognitive impairment in progressive supranuclear palsy.
Improving dementia care within primary care requires a transformation in care processes with an emphasis on interprofessional collaboration between family physicians, allied health professionals and specialists.
This study suggests that correct use of cognitive screening instruments may conveivably help to narrow the ‘dementia diagnosis gap’.
This study attempts to identify the published measurements of Huntington’s disease prevalence and reconcile the geographical variations in HD prevalence.
This article reviews the field of amyloid-beta immunotherapy for the treatment of Alzheimer’s disease.
This article puts forward the argument that neuropathology is not obsolete within dementia research, despite advances in neuroimaging and molecular biology techniques.